Previous 10 | Next 10 |
While certainly not always the case, investors ignoring or apathetic to names or sectors can be a sign of looming bullishness. In the cycle of Sentiment, Panic, Capitulation and Despondency often mark the extreme bottoms. However; Depression, Apathy and Indifference are often realized while ...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 102 weeks of public selections as part of this ongoing live forward-testing. In...
Putting the cart before the horse The typical course of drug R&D goes something like this: a druggable target is identified early discovery efforts are launched a lead drug candidate is selected preclinical studies are conducted an IND is filed PhI, PhII and PhIII trials ar...
Marinus Pharmaceuticals (NASDAQ: MRNS ): Q1 GAAP EPS of -$0.24 misses by $0.02. Cash and Cash equivalents of $60.8M Press Release More news on: Marinus Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
RADNOR, Pa., May 01, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development act...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 102 weeks of public selections as part of this ongoing live forward-testing. In...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years, including nearly 100 weeks of public selections as part of this ongoing live forward-testing. In 2017, the sample size began with 12 stocks, then 8 stocks ...
From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years including 98 weeks of public weekly selections as part of this ongoing live forward-testing. In 2017, the sample size began with 12 stocks, then 8 stocks in...
The US Food and Drug Administration (FDA) handed out its first-ever approval for the treatment of postpartum depression (PPD) on Tuesday (March 19) to biopharmaceutical giant Sage Therapeutics (NASDAQ: SAGE ). Called Zulresso (generic name brenaxolone), the drug will be available ...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...